Last reviewed · How we verify
Standard heart failure medical therapy
At a glance
| Generic name | Standard heart failure medical therapy |
|---|---|
| Sponsor | Finn Gustafsson |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ablation Versus Medical Management of Atrial Fibrillation in HFpEF (NA)
- Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (NA)
- Telemedicine-Based Integrated Care for Heart Failure Prevention in Older Patients With Atrial Fibrillation (MIRACLE-AF III) (NA)
- Multi-Center Project: Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (NA)
- Telemedicine-based Integrated Management of Atrial Fibrillation and Heart Failure in Older Patients in Village Clinics (NA)
- Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years (NA)
- Medication Withdrawal in Stable HF With Improved LVEF (PHASE2, PHASE3)
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard heart failure medical therapy CI brief — competitive landscape report
- Standard heart failure medical therapy updates RSS · CI watch RSS
- Finn Gustafsson portfolio CI